Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Prediction of oxygen uptake during walking in ambulatory persons with multiple sclerosis.
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction.
Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients.
The Role of Endogenous IFN-β in the Regulation of Th17 Responses in Patients with Relapsing-Remitting Multiple Sclerosis.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Interferon-beta(1b) treatment in neuromyelitis optica.
Statement on a nonproprietary name adopted by the USAN Council
Glatiramer Acetate Guards Against Rapid Memory Decline During Relapsing-Remitting Experimental Autoimmune Encephalomyelitis.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis.
Antibody producing B lineage cells invade the central nervous system predominantly at the time of and triggered by acute Epstein-Barr virus infection: A hypothesis on the origin of intrathecal immunoglobulin synthesis in multiple sclerosis.
Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.
Individual oligodendrocytes have only a few hours in which to generate new myelin sheaths in vivo.
Estrogen treatment in multiple sclerosis.
Correction: Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.
European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab)
Chemical and Biological Therapeutic Approaches to Neurological Disorders III
Biomarkers for Brain Disorders: Challenges and Opportunities

Pages